The effect of opportunistic salpingectomy for primary prevention of ovarian cancer on ovarian reserve: a systematic review and meta-analysis

Maturitas. 2022 Dec:166:21-34. doi: 10.1016/j.maturitas.2022.08.002. Epub 2022 Aug 17.

Abstract

Background: Opportunistic salpingectomy (OS) is an attractive method for primary prevention of ovarian cancer. Although OS has not been associated with a higher complication rate, it may be associated with earlier onset of menopause.

Objective: To provide a systematic review and meta-analysis of the effect of OS on both age at menopause and ovarian reserve.

Methods: A search was conducted in the Cochrane Library, Embase and MEDLINE databases from inception until March 2022. We included randomized clinical trials and cohort studies investigating the effect of OS on onset of menopause and/or ovarian reserve through change in anti-Müllerian hormone (AMH), antral follicle count (AFC), estradiol (E2), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Data was extracted independently by two researchers. Random-effects meta-analyses were conducted to estimate the pooled effect of OS on ovarian reserve.

Results: The initial search yielded 1047 studies. No studies were found investigating the effect of OS on age of menopause. Fifteen studies were included in the meta-analysis on ovarian reserve. Meta-analyses did not result in statistically significant differences in mean change in AMH (MD -0.07 ng/ml, 95%CI -0.18;0.05), AFC (MD 0.20 n, 95 % CI -4.91;5.30), E2 (MD 3.97 pg/ml, 95%CI -0.92;8.86), FSH (MD 0.33mIU/ml, 95%CI -0.15;0.81) and LH (MD 0.03mIU/ml; 95%CI -0.47;0.53).

Conclusion: Our study shows that OS does not result in a significant reduction of ovarian reserve in the short term. Further research is essential to confirm the absence of major effects of OS on menopausal onset since clear evidence on this subject is lacking. Registration number PROSPERO CRD42021260966.

Keywords: Menopausal age; Menopause; Opportunistic salpingectomy; Ovarian cancer; Ovarian reserve; Prevention.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Anti-Mullerian Hormone
  • Female
  • Follicle Stimulating Hormone
  • Humans
  • Luteinizing Hormone
  • Ovarian Neoplasms* / prevention & control
  • Ovarian Reserve*
  • Primary Prevention
  • Salpingectomy / methods

Substances

  • Follicle Stimulating Hormone
  • Luteinizing Hormone
  • Anti-Mullerian Hormone